ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Establishment of molecular subtypes and prognostic models for glioblastoma based on non-apoptotic regulatory cell death genes.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-apoptotic regulatory cell death (NARCD) encompasses a range of cell death mechanisms beyond apoptosis. It plays a crucial role in the development and progression of brain gliomas; however, the specific regulatory mechanisms involved remain insufficiently explored. This study aims to construct a prognostic model to predict disease progression based on the potential mechanisms of NARCD-related genes in brain gliomas.
methodsmRNA expression profiles and clinical data of brain glioma patients were downloaded from The Cancer Genome Atlas (TCGA) database. Control gene expression profiles were obtained from the Genotype-Tissue Expression (GTEx) project. The external validation set was sourced from the Chinese Glioma Genome Atlas (CGGA). Molecular subtyping was performed using unsupervised clustering, and functional analysis was conducted on the differentially expressed genes among the subtypes. A NARCD-related prognostic model was developed using univariate Cox, LASSO, and multivariate Cox regression analysis. Subsequently, patients were stratified into high- and low-risk groups, and comprehensive validations were performed to evaluate the prognostic value of the model. Additionally, the associations between the prognostic model, immune infiltration, and drug sensitivity were explored. Quantitative PCR (q-PCR) experiments were conducted to validate the expression of nine key genes.
resultsThis study categorized brain glioma patients into three subtypes based on key NARCD genes. A prognostic risk model was established using nine differential genes among the three subtypes. Patients with high-risk scores exhibited poorer overall prognosis. Furthermore, in the high-risk population, we observed reduced immune cell infiltration, suppressed immune function, and elevated tumor mutation burden (TMB). Patients in the low-risk group were more sensitive to drugs than those in the high-risk group. The q-PCR results for the characteristic genes were in agreement with the outcomes of the model analysis.
conclusionThe NARCD-related prognostic model established in this study serves as a reliable biomarker for predicting clinical outcomes in brain glioma patients, assessing immune infiltration status, and forecasting drug sensitivity.
Indexed as
Identifiers
41071456What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.